This HTML5 document contains 48 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
dctermshttp://purl.org/dc/terms/
n5http://localhost/temp/predkladatel/
n4http://linked.opendata.cz/resource/domain/vavai/riv/tvurce/
n17http://linked.opendata.cz/ontology/domain/vavai/
shttp://schema.org/
skoshttp://www.w3.org/2004/02/skos/core#
n3http://linked.opendata.cz/ontology/domain/vavai/riv/
n11http://linked.opendata.cz/resource/domain/vavai/vysledek/RIV%2F00216208%3A11120%2F14%3A43908598%21RIV15-MSM-11120___/
n2http://linked.opendata.cz/resource/domain/vavai/vysledek/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n6http://linked.opendata.cz/ontology/domain/vavai/riv/klicoveSlovo/
n12http://linked.opendata.cz/ontology/domain/vavai/riv/duvernostUdaju/
xsdhhttp://www.w3.org/2001/XMLSchema#
n16http://linked.opendata.cz/ontology/domain/vavai/riv/aktivita/
n8http://linked.opendata.cz/ontology/domain/vavai/riv/jazykVysledku/
n15http://linked.opendata.cz/ontology/domain/vavai/riv/druhVysledku/
n13http://linked.opendata.cz/ontology/domain/vavai/riv/obor/
n9http://reference.data.gov.uk/id/gregorian-year/

Statements

Subject Item
n2:RIV%2F00216208%3A11120%2F14%3A43908598%21RIV15-MSM-11120___
rdf:type
skos:Concept n17:Vysledek
dcterms:description
The aim of this study was to assess the CTC-positivity rate in patients undergoing chemotherapy depending on breast cancer stage in the adjuvant and neoadjuvant setting. We evaluated the ability to confirm therapy response by CTC analysis. Patients and Methods: CTCs isolated from blood by means of immunomagnetic separation were further characterized by means of reverse transcriptase polymerase chain reaction (RT-PCR) for epithelial cell adhesion molecule (EPCAM), mucin 1 (MUC1) and v-erb-b2 avian erythroblastic leukemia viral oncogene homolog 2 (HER2) transcripts with the AdnaTest (TM). This prospective study included 179 patients; altogether 419 blood samples were evaluated. Patients with primary tumors were divided into neoadjuvant (n=38), and adjuvant (n=100) groups. Forty-one patients with MBC were evaluated under palliative treatment. Results: CTC positivity was described in 35% of patients with early breast cancer without detected metastases before neoadjuvant chemotherapy; similarly, a 26% positivity rate was found in the adjuvant group. In patients with MBC, we detected CTCs in 43% of them. After completing the therapy, the CTC positivity rate decreased to 5% in the neoadjuvant group, to 13% in the adjuvant group and to 12% in the MBC group. CTC positivity after the therapy may classify a subgroup of patients at high risk of developing metastatic disease. This was even true when a patient was evaluated as being CTC-negative before chemotherapy. The multivariate analysis evaluating the correlation of CTC positivity with clinicopathological characteristics such as tumor size, nodal involvement, hormone receptor status, HER2 expression and number of metastatic sites revealed no statistically significant relationships. Conclusion: CTC status may have a significant impact on early BC management. The aim of this study was to assess the CTC-positivity rate in patients undergoing chemotherapy depending on breast cancer stage in the adjuvant and neoadjuvant setting. We evaluated the ability to confirm therapy response by CTC analysis. Patients and Methods: CTCs isolated from blood by means of immunomagnetic separation were further characterized by means of reverse transcriptase polymerase chain reaction (RT-PCR) for epithelial cell adhesion molecule (EPCAM), mucin 1 (MUC1) and v-erb-b2 avian erythroblastic leukemia viral oncogene homolog 2 (HER2) transcripts with the AdnaTest (TM). This prospective study included 179 patients; altogether 419 blood samples were evaluated. Patients with primary tumors were divided into neoadjuvant (n=38), and adjuvant (n=100) groups. Forty-one patients with MBC were evaluated under palliative treatment. Results: CTC positivity was described in 35% of patients with early breast cancer without detected metastases before neoadjuvant chemotherapy; similarly, a 26% positivity rate was found in the adjuvant group. In patients with MBC, we detected CTCs in 43% of them. After completing the therapy, the CTC positivity rate decreased to 5% in the neoadjuvant group, to 13% in the adjuvant group and to 12% in the MBC group. CTC positivity after the therapy may classify a subgroup of patients at high risk of developing metastatic disease. This was even true when a patient was evaluated as being CTC-negative before chemotherapy. The multivariate analysis evaluating the correlation of CTC positivity with clinicopathological characteristics such as tumor size, nodal involvement, hormone receptor status, HER2 expression and number of metastatic sites revealed no statistically significant relationships. Conclusion: CTC status may have a significant impact on early BC management.
dcterms:title
Circulating tumor cells in patients with breast cancer: monitoring chemotherapy success Circulating tumor cells in patients with breast cancer: monitoring chemotherapy success
skos:prefLabel
Circulating tumor cells in patients with breast cancer: monitoring chemotherapy success Circulating tumor cells in patients with breast cancer: monitoring chemotherapy success
skos:notation
RIV/00216208:11120/14:43908598!RIV15-MSM-11120___
n3:aktivita
n16:I
n3:aktivity
I
n3:cisloPeriodika
4
n3:dodaniDat
n9:2015
n3:domaciTvurceVysledku
n4:8209766 n4:5704995 n4:6868037 n4:8978182 n4:9313605 n4:2394685
n3:druhVysledku
n15:J
n3:duvernostUdaju
n12:S
n3:entitaPredkladatele
n11:predkladatel
n3:idSjednocenehoVysledku
7325
n3:idVysledku
RIV/00216208:11120/14:43908598
n3:jazykVysledku
n8:eng
n3:klicovaSlova
circulating tumor cells; chemotherapy; breast cancer; CTC
n3:klicoveSlovo
n6:circulating%20tumor%20cells n6:breast%20cancer n6:chemotherapy n6:CTC
n3:kodStatuVydavatele
GR - Řecká republika
n3:kontrolniKodProRIV
[3E06B99E0409]
n3:nazevZdroje
In Vivo
n3:obor
n13:FD
n3:pocetDomacichTvurcuVysledku
6
n3:pocetTvurcuVysledku
9
n3:rokUplatneniVysledku
n9:2014
n3:svazekPeriodika
28
n3:tvurceVysledku
Brychta, Milan Kološtová, Katarína Bobek, Vladimír Kubecová, Martina Valchář, Josef Pintérová, Daniela
n3:wos
000338777500026
s:issn
0258-851X
s:numberOfPages
10
n5:organizacniJednotka
11120